Apeiron Therapeutics to Present FiH Phase 1 Data on PRMT5 Inhibitor GTA182 at ESMO Asia 2025
SAN FRANCISCO, CA, Nov. 24, 2025 – Apeiron Therapeutics (Apeiron), a precision oncology company leveraging state-of-the-art structural biology and AI-guided molecular modeling for drug discovery, today announced that clinical data from its clinical-stage PRMT5-inhibitor program, GTA182, will be presented in a late-breaking mini oral session at the European Society for Medical Oncology (ESMO) Asia 2025 Congress, taking place December 5–7, 2025, in Singapore.
GTA182, a potent and selective MTA-cooperative PRMT5 inhibitor, is currently being evaluated in an ongoing Phase 1 clinical trial for patients with MTAP-deleted malignancies. The oral presentation will highlight emerging clinical findings from the first-in-human study.
Details of the ESMO Asia Presentation
Title: First-in-Human Phase 1 Study of GTA182, a Novel MTA-Cooperative PRMT5 Inhibitor, in Patients with MTAP-Deleted Advanced Non-Small Cell Lung Cancer
Session Category: Mini Oral Session 1: Thoracic Malignancies
Presenting Author: Shun Lu, MD, PhD
Session Link: https://cslide.ctimeetingtech.com/asia2025/attendee/confcal/show/session/77
Lecture Time: 10:45 AM SGT
Session Date and Time: December 5, 2025, 10:45 AM – 12:15 PM SGT
Location: Hall 405, Suntec Singapore, Singapore
Presentation Number: LBA14
All presentations and posters will be available to registered attendees for on-demand viewing on the ESMO website.
About GTA182
GTA182 is a proprietary small molecule discovered through Apeiron’s AI-guided drug discovery platform. Currently in Phase 1 clinical development, GTA182 demonstrated potent and selective inhibition of PRMT5, exhibiting over 100-fold selectivity for MTAP-deleted tumor cell lines. Importantly, GTA182 is brain-penetrant and has shown tumor growth inhibition and regression in in vivo preclinical models, including glioblastoma (GBM) and various non-CNS cancer models with MTAP deletions.
About Apeiron Therapeutics
Apeiron is redefining medical discovery through the integration of artificial intelligence, streamlining the drug development process from target selection to clinical trials. With a strategic presence in the San Francisco Bay Area, Apeiron combines world-class talent and cutting-edge technologies to drive biomedical innovation. We are committed to advancing breakthrough therapies that address the most pressing unmet medical needs.
For more information, please visit https://www.apeiron-bio.com.
Investor and Media Contact
Silinda Neou
